ID: ALA418226

Max Phase: Preclinical

Molecular Formula: C25H25N5O

Molecular Weight: 411.51

Molecule Type: Small molecule

Representations

Synonyms (1): ZD-6888
Synonyms from Alternative Forms(1):

Canonical SMILES:  CCc1cc(OCc2ccc(-c3ccccc3-c3nn[nH]n3)cc2)c2c(n1)CCCC2

Standard InChI:  InChI=1S/C25H25N5O/c1-2-19-15-24(22-9-5-6-10-23(22)26-19)31-16-17-11-13-18(14-12-17)20-7-3-4-8-21(20)25-27-29-30-28-25/h3-4,7-8,11-15H,2,5-6,9-10,16H2,1H3,(H,27,28,29,30)

Standard InChI Key:  AWZMTWHHQXOWQR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 411.51

Molecular Weight (Monoisotopic): 411.2059

AlogP: 4.95

#Rotatable Bonds: 6

Polar Surface Area: 76.58

Molecular Species: ACID

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.85

CX Basic pKa: 7.90

CX LogP: 4.10

CX LogD: 4.19

Aromatic Rings: 4

Heavy Atoms: 31

QED Weighted: 0.49

Np Likeness Score: -0.79

References

1. Bradbury RH, Allott CP, Dennis M, Girdwood JA, Kenny PW, Major JS, Oldham AA, Ratcliffe AH, Rivett JE, Roberts DA..  (1993)  New nonpeptide angiotensin II receptor antagonists. 3. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)pyridine derivatives.,  36  (9): [PMID:8487261] [10.1021/jm00061a016]

2. Bradbury R, Edwards M, Fisher E, Girdwood J, Major J, Oldham A, Patel M, Pearce R, Revill J, Ratcliffe A.  (1994)  New nonpeptide angiostensin II receptor antagonists. Synthesis, biological properties and structure-activity relationships of 3-substituted 2,6-dialkyl-4-(biphenyll)methylaminopyridine derivatives.,  4  (1): [10.1016/S0960-894X(01)81136-7]

3. Thomas AP, Roberts DA, Thomason DA.  (1994)  The synthesis and biological activity of tetrahydroquinoline angiotensin II antagonists containing a substituted biphenyltetrazole group,  4  (21): [10.1016/S0960-894X(01)80295-X]

4. Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD, Timmermans PB..  (1996)  Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.,  39  (3): [PMID:8576904] [10.1021/jm9504722]

5. Naik P, Murumkar P, Giridhar R, Yadav MR..  (2010)  Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.,  18  (24): [PMID:21071232] [10.1016/j.bmc.2010.10.043]

6. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data